Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

MetricGMABGenmab A/SABVXAbivax SAINCYIncyte
Snapshot
Price$28.11$145.95$116.86
Market cap$16.18B$11.63B$23.35B
Valuation
P/E20.9x—16.3x
Forward P/E27.9x—11.7x
Growth
Revenue growth20.7%—21.5%
EPS growth-25.3%—2455.3%
Profitability
Net margin21.1%—26.7%
ROE14.5%-51.7%29.2%
Balance sheet & cash
Debt / equity0.93x0x0.01x
Free cash flow yield—-2.1%2.2%
Dividend yield———
Verdict
Investment ratingFavorable· 62Weak· 35Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearGMABtoday $28ABVXtoday $146INCYtoday $117
2027$21.50 – $31.54+12% CAGR$117.12 – $171.78+18% CAGR$2,239.60 – $3,284.75+2711% CAGR
2028$21.93 – $32.17+7% CAGR$125.32 – $183.81+12% CAGR$57,228.76 – $83,935.51+2580% CAGR
2029$22.37 – $32.81+5% CAGR$134.10 – $196.67+10% CAGR$1,462,372.22 – $2,144,812.59+2538% CAGR
2030$22.82 – $33.47+4% CAGR$143.48 – $210.44+10% CAGR$37,368,143.63 – $54,806,610.65+2517% CAGR
2031$23.28 – $34.14+4% CAGR$153.53 – $225.17+9% CAGR$954,871,910.91 – $1,400,478,802.66+2504% CAGR
5-yr CAGR-3.7% – 4.0%1.0% – 9.1%2312.4% – 2504.5%